BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6627216)

  • 1. Immunosuppressive acidic protein in patients with ovarian cancer.
    Sawada M; Okudaira Y; Matsui Y; Shimizu Y
    Cancer; 1983 Dec; 52(11):2081-5. PubMed ID: 6627216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunosuppressive acidic protein in patients with gynecologic cancer].
    Sawada M; Matsui Y; Okudaira Y; Shimizu Y; Takayama K
    Nihon Sanka Fujinka Gakkai Zasshi; 1983 May; 35(5):605-11. PubMed ID: 6408203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive acidic protein in patients with gynecologic cancer.
    Sawada M; Okudaira Y; Matsui Y; Shimizu Y
    Cancer; 1984 Aug; 54(4):652-6. PubMed ID: 6744202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of immunosuppressive acidic protein in the diagnosis and follow-up of patients with ovarian cancer, in particular as a marker for chemotherapeutic effects].
    Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y; Kurachi K
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Apr; 38(4):554-60. PubMed ID: 3701144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of immunosuppressive acidic protein in human ovarian cancer.
    Lin YH; Chow SN; Chen CK; Chen RJ; Huang SC; Huang GT
    J Formos Med Assoc; 1994 Sep; 93(9):776-80. PubMed ID: 7735007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Studies on immunosuppressive acidic protein (IAP) in ovarian tumors].
    Miyoshi T; Nishimura H; Hamai J; Yamada T; Tomoo Y; Kobayashi H; Yakushiji M; Kato T
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):923-9. PubMed ID: 2991397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Variations in the level of immunosuppressive acidic protein in patients with gynecologic tumors and pregnant women].
    Sawada M; Okudaira Y; Matsui Y; Miyoshi Y; Takayama K; Shimizu Y; Miura S
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1823-30. PubMed ID: 6882005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of carcinoma of the pancreas by assay of immunosuppressive acidic protein.
    Matsuno S; Kobari M; Matsuda Y; Sato T
    Tohoku J Exp Med; 1982 Jan; 136(1):1-10. PubMed ID: 7071823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study on the serum carcinoembryonic antigen, immunosuppressive acidic protein and C-reactive protein levels in patients with adult T cell leukemia].
    Kumagai E; Ogata M; Maeda Y; Kumagai T; Okajima K; Yamaguchi K; Tanoue S
    Rinsho Byori; 1989 Jul; 37(7):769-73. PubMed ID: 2607647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive acidic protein (IAP) and CA 125 assays in detection of human ovarian cancer: preliminary results.
    Castelli M; Romano P; Atlante G; Pozzi M; Ferrini U
    Int J Biol Markers; 1987; 2(3):187-90. PubMed ID: 3482661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer.
    Castelli M; Battaglia F; Scambia G; Panici PB; Ferrandina G; Mileo AM; Mancuso S; Ferrini U
    Oncology; 1991; 48(1):13-7. PubMed ID: 1987493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.
    Koebl H; Tatra G; Bieglmayer C
    Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An evaluation of carcinoembryonic antigen (CEA), beta 2-microglobulin (BMG), and immunosuppressive acidic protein (IAP) in the serum of primary lung cancer patients].
    Higuchi Y
    Gan No Rinsho; 1986 Jan; 32(1):33-40. PubMed ID: 3005690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination assay of CA125, TPA, IAP, CEA, and ferritin in serum for ovarian cancer.
    Yabushita H; Masuda T; Ogawa A; Noguchi M; Ishihara M
    Gynecol Oncol; 1988 Jan; 29(1):66-75. PubMed ID: 3422208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of immunosuppressive acidic protein (IAP) in patients with renal cell cancer].
    Shibayama T; Nakazono M; Koyama Y; Deguchi N; Baba S; Jitsukawa S; Murai M; Tazaki H
    Gan No Rinsho; 1984 May; 30(5):481-6. PubMed ID: 6727048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ["Immunosuppressive acidic protein" (IAP)--an improvement for tumor marker diagnosis in epithelial ovarian cancer?].
    Sevelda P; Haider F; Spona J
    Geburtshilfe Frauenheilkd; 1987 Jul; 47(7):452-5. PubMed ID: 3476335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
    Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive substance in the sera of head and neck cancer patients.
    Yamanaka N; Harabuchi Y; Himi T; Kataura A
    Cancer; 1988 Oct; 62(7):1293-8. PubMed ID: 3416271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of measurement of immunosuppressive acidic protein (IAP) in lung cancer].
    Kondo H; Seno N; Matsuo S; Otagaki S; Matsuki T; Hatayama T
    Gan To Kagaku Ryoho; 1983 Oct; 10(10):2163-70. PubMed ID: 6625623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of serum immunosuppressive acidic protein (IAP) and acid soluble glycoproteins (ASP) in patients with malignant tumors].
    Shibasaki K; Soga K; Toshima M; Aikawa K; Tsuruya T; Itoh T; Takahashi Y; Tsuchimochi M; Mataga I; Tsuchikawa K
    Shigaku; 1989 Aug; 77(2):701-11. PubMed ID: 2489324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.